Clinical Trial

A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the PK and safety of ublituximab SC at different sites of administration and relative bioavailability of ublituximab SC administered with a prefilled pen versus syringe.
Protocol Amendment History 5 changes
critical Primary endpoint(s) modified 2026-07-21
notable Trial sites expanded: 36 -> 39 locations 2026-07-21
notable Primary completion moved earlier: 2027-07-31 -> 2027-05-30 2026-07-21
critical Recruitment opened 2026-07-08
notable Trial sites expanded: 0 -> 36 locations 2026-07-08
Trial Details
NCT Number NCT07503873
Lead Sponsor TG Therapeutics, Inc.
Conditions Multiple Sclerosis
Enrollment 350 participants
Start Date 2026-04-01
Primary Completion 2027-05-30 (estimated)
Study Completion 2029-05-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-20